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Abstract
Background and Purpose: Diagnosis of paroxysmal atrial fibrillation (AF) can be challenging, but it is highly relevant in
patients presenting with sinus rhythm and acute cerebral ischemia. We aimed to evaluate prospectively whether natriuretic
peptide levels and kinetics identify patients with paroxysmal AF.
Methods: Patients with acute cerebral ischemia were included into the prospective observational Find-AF study. N-terminal
pro brain-type natriuretic peptide (NT-proBNP), brain-type natriuretic peptide (BNP) and N-terminal pro atrial-type
natriuretic peptide (NT-proANP) plasma levels were measured on admission, after 6 and 24 hours. Patients free from AF at
presentation received 7 day Holter monitoring. We prospectively hypothesized that patients presenting in sinus rhythm
with NT-proBNP.median were more likely to have paroxysmal AF than patients with NT-proBNP,median.
Results: 281 patients were included, of whom 237 (84.3%) presented in sinus rhythm. 220 patients naı ¨ve to AF with an
evaluable prolonged Holter ECG were analysed. In patients with NT-proBNP.median (239 pg/ml), 17.9% had paroxysmal AF
in contrast to 7.4% with NT-proBNP,239 pg/ml (p=0.025). The ratio of early (0 h) to late (24 h) plasma levels of NT-proBNP
showed no difference between both groups. For the detection of paroxysmal atrial fibrillation, BNP, NT-proBNP and NT-
proANP at admission had an area under the curve in ROC analysis of 0.747 (0.663–0.831), 0.638 (0.531–0.744) and 0.663
(0.566–0.761), respectively. In multivariate analysis, BNP was the only biomarker to be independently predictive for
paroxysmal atrial fibrillation.
Conclusions: BNP is independently predictive of paroxysmal AF detected by prolonged ECG monitoring in patients with
cerebral ischemia and may be used to effectively select patients for prolonged Holter monitoring.
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Introduction
Atrial fibrillation (AF) is a frequent cause of ischemic stroke and
patients with atrial fibrillation bear an increased risk for suffering a
recurrent stroke [1,2]. Diagnosis of AF in patients with ischemic
stroke usually results in a change of therapy with oral
anticoagulation being the most effective strategy for secondary
prevention of ischemic events [3,4]. Identification of paroxysmal
AF after cerebral ischemia and initiation of appropriate therapy
can therefore be expected to lower morbidity from recurrent
stroke. Unfortunately, patients with paroxysmal AF may be
asymptomatic until the occurrence of a cerebral embolic event.
Identifying paroxysmal AF may be challenging in these subjects if
they are in sinus rhythm at the time of hospitalisation. Prolonged
[5] or continued [6] rhythm monitoring may enhance the
detection of clinically ‘silent’ paroxysmal AF, but being expensive,
time-consuming in terms of evaluation as well as cumbersome for
the patient, broad application of such enhanced diagnostics may
not be readily available for all unselected patients presenting with
cerebral ischemia of unknown cause and sinus rhythm on
admission.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34351Natriuretic peptides have been widely used in different clinical
settings and have been shown to be predictive of AF within the
general population [7] as well as in patients undergoing surgical
procedures [8]. Moreover, numerous studies have shown an
elevation of natriuretic peptide levels in AF [9,10] which decrease
after conversion [11,12] to sinus rhythm. Thus, we hypothesized
that natriuretic peptide levels as well as the ratio of early (0 h) to
late (24 h) plasma level of a natriuretic peptide may identify acute
stroke patients with paroxysmal AF.
Materials and Methods
Patients
Find-AF is a single center prospective observational trial
(ISRCTN 46104198). Details on patient recruitment and
detection rate of Holter monitoring have recently been published
[5]. The present analysis aimed to determine whether a blood test
(plasma levels of natriuretic peptides) can help risk stratification in
patients with cerebral ischemia to further more intensive
diagnostics (7 d-Holter ECG). We included consecutive patients
presenting to the emergency department of the University of
Go ¨ttingen between March 2009 and February 2010 with
symptoms of stroke or transient ischemic attack (TIA). Patients
who were found to have other definitive diagnoses (e.g.
intracranial bleeding) causative for their symptoms were excluded,
all others were asked to confirm preliminary consent by signature.
Exclusion criteria were age ,18 years or inability or unwillingness
to consent. The study complies with the Declaration of Helsinki,
the protocol was approved by the responsible ethics committee of
the University of Go ¨ttingen and all patients gave written informed
consent.
Data collection and clinical evaluation
Baseline characteristics were recorded by a standardised
questionnaire, including detailed medical history and baseline
medication. Patients underwent serial biomarker sampling at 0 h,
6 h and 24 h after presentation to the emergency department and
received carotid ultrasound as well as cerebral imaging (computed
tomography or magnetic resonance imaging). After written
informed consent was obtained, patients without AF at baseline
received a Holter monitor (CardioMemH CM 3000, getemed
Medizin- und Informationstechnik, Teltow, Germany) which was
applied by specifically trained study personnel (R.C.L. and B.H.).
These devices are capable of recording a period of up to 10 days
with a single charge of batteries on a secure digital storage card.
Patients and relatives were instructed in the correct handling of the
monitors. The Holter monitors were collected after 7 days.
Patients discharged earlier were instructed to send back the devices
after the monitoring period had elapsed.
Plasma levels of NT-proBNP were measured using a sandwich
enzyme immunoassay (Roche Diagnostics, Mannheim, Germany).
NT-proANP was analysed with an ELISA (Biomedica, Wien,
Austria). BNP was measured by means of a sandwich chemilumi-
nescence immunoassay on a Centaur (Bayer Vital, Leverkusen,
Germany). Personnel responsible for the determination of
natriuretic peptide levels were blinded to clinical patient data.
Definition of the primary endpoint
The primary hypothesis of Find-AF was that higher NT-
proBNP levels on admission and thus can discriminate patients
with paroxysmal AF from those without AF. As natriuretic
peptides have been shown to fall rapidly after conversion of AF to
sinus rhythm, we also investigated the ratio of early (0 h) to late
(24 h) plasma levels of NT-proBNP. Furthermore, we measured
both BNP (which is measured in many institutions instead of NT-
proBNP), and NT-proANP, which is a more stable precursor of
atrial natriuretic peptide and may be more specific for atrial
hemodynamic stress than the BNPs.
We assumed that 20% of the patients with NT-proBNP above
median and 5% of those with NT-proBNP below median had
paroxysmal AF [13]. To detect a difference with a two-sided
a=0.05 and power of 90%, 101 study participants per group (202
overall) would be necessary. Considering a rate of 10% of ECGs
not evaluable and drop-outs, we planned to include 225 patients.
Definitions and Statistical Analyses
Continuous data are given as mean 6 standard deviation,
unless otherwise stated. Categorical variables are given as absolute
numbers (percent) and were compared by Chi-square or Fisher’s
exact test. Normally distributed data were compared by student’s t
test, not normally distributed data by Mann-Whitney-U-Test. To
investigate relations between variables, bivariate Pearson’s corre-
lations were calculated. To elucidate the independency of
association with paroxysmal AF, we performed multivariate
analyses with age, sex, body mass index, systolic blood pressure,
estimated glomerular filtration rate (eGFR), coronary artery
disease, presence of heart failure, left atrial diameter, left
ventricular ejection fraction, left ventricular mass index and left
ventricular enddiastolic diameter as covariables and added
natriuretic peptide plasma levels on admission or 0/24 h ratios
individually to the base model. Receiver operating characteristics
(ROC) curves were used to describe test characteristics. Etiology of
stroke was classified according to the widely used TOAST
classification scheme and was performed by one of the neurologists
(J.W. or K.G.). Stroke severity was approximated by video trained
physicians applying the NIH stroke scale (NIH-SS) and the
modified Rankin Scale (mRS). Presence of paroxysmal AF was
defined as at least one period of more than 30 seconds duration of
an absolute arrhythmia without detectable P waves and without a
pattern more consistent with an alternative diagnosis, as
recommended and described previously [5]. Detected episodes
were verified by a specialist in electrophysiology (J.S.) blinded to
clinical data and natriuretic peptide levels. The analysis included
only those 220 patients who were naive to AF and had an
evaluable Holter ECG. Statistical tests were performed with SPSS
Statistics 19.0.0 (IBM, Chicago, Illinois, USA). Values of
natriuretic peptides were not normally distributed and were thus
logarithmised for correlation and logistic regression analysis.
Results
Study population
281 consecutive patients were included, of whom 44 (15.7%)
had AF at presentation. All remaining patients (n=237)
underwent Holter monitoring. Clinical characteristics of the
complete cohort have previously been reported [5]. One patient
withdrew consent. For the present analysis, we excluded patients
with a final diagnosis other than cerebral ischemia (n=7), those
with Holter ECGs that could not be analysed (n=5) and those
with previously diagnosed paroxysmal AF (n=4), see also figure 1.
Of the remaining 220 patients, 28 (12.7%) had paroxysmal AF
(n=26) or atrial flutter (n=2) on Holter monitoring. Table 1
shows clinical characteristics of the 28 patients with paroxysmal
AF and the 192 patients without paroxysmal AF. The median
CHADS2 score in patients with paroxysmal AF was 3.8.
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Table 2 shows levels of NT-proBNP, BNP and NT-proANP at
three different time-points (0 h, 6 h, 24 h) as well as the ratio of
early (0 h) to late (24 h) plasma levels. All natriuretic peptides were
significantly higher in patients with paroxysmal AF at each time
point, but the ratio of early to late plasma levels were not different
between those with and without paroxysmal atrial fibrillation. The
median NT-proBNP level at 0 h was 239 pg/ml; the median ratio
of early to late plasma NT-proBNP-level was 0.78. Figure 2 shows
the primary parameters of the study: The prevalence of
paroxysmal AF in study participants with a NT-proBNP above
the median was 17.9% compared to 7.4% in patients below the
median NT-proBNP (p=0.025). The prevalence of paroxysmal
AF between study participants with a ratio of early/late NT-
proBNP above median was not different to those with a ratio
below median (p=0.200). Of note, BNP and NT-proBNP both
correlated with NIH-SS (r=0.196, p=0.010 and r=0.176,
p=0.014, respectively) and mRS (r=0.248, p=0.001 and
r=0.257, p,0.001, respectively), whereas log NT-proANP did
neither correlate with NIH-SS (r=0.103, p=0.153) nor with mRS
(r=0.139, p=0.054). All natriuretic peptides correlated with age
(r=0.417, r=0.231 and r=0.373 for BNP, NT-proANP and NT-
proBNP, respectively, all p#0.001). Similar correlations were
found for BNP and NT-proANP.
None of the natriuretic peptides showed a significant correlation
with the cumulative time in AF during the 7-day Holter ECG. Of
note, natriuretic peptides between patients with paroxysmal atrial
fibrillation and the 44 patients with AF on admission were not
significantly different.
Diagnostic utility of natriuretic peptides
We performed receiver-operating characteristic analysis to
determine the diagnostic utility of natriuretic peptides for the
detection of paroxysmal AF. Figure 3 shows the ROC curves for
NT-proBNP, BNP and NT-proANP plasma levels on admission.
The area under the curve was 0.638 (95% CI: 0.531–0.744) for
NT-proBNP, 0.747 (95% CI: 0.663–0.831) for BNP and 0.663
(95% CI: 0.566–0.761) for NT-proANP. The combination of two
different natriuretic peptides did not show incremental value.
Table 3 shows test characteristics for different BNP cut-offs.
As patients with systolic heart failure have elevated NT-proBNP
plasma levels, we performed a subgroup analysis and excluded all
patients with an ejection fraction ,50% (n=15). This did not
substantially alter the results. In multivariate analyses with age,
sex, body mass index, systolic blood pressure, estimated glomer-
ular filtration rate, coronary artery disease and presence of heart
failure as covariables, baseline BNP was the only natriuretic
peptide to be independently predictive for the presence of
paroxysmal AF on 7 d Holter monitoring (corrected odd’s ratio
6.1 per ten-fold BNP, 95% CI 1.7 to 22.4, p=0.006).
Discussion
To the best of our knowledge this study tested for the first time
prospectively a biomarker-guided approach to predict paroxysmal
AF in patients with acute cerebral ischemia and sinus rhythm at
the time of initial presentation.
Our study has three major findings:
(1) Natriuretic peptide plasma levels are significantly higher in
patients with paroxysmal AF compared to those without.
(2) The kinetics of natriuretic plasma levels within the first 24 h
after admission do not differ between patients with paroxys-
mal AF and those without.
(3) BNP was independently predictive for paroxysmal AF as
detected by highly sensitive 7 d Holter monitoring while
NTproBNP and NTproANP were not.
Natriuretic peptides have been shown to be predictive for future
AF in a number of different clinical settings [8,14], including the
general population [7,15]. However, no previous study has
evaluated its usefulness for the detection of paroxysmal AF. Our
results are to some extent in line with previous data presented in a
recent work of Okada et al. [16]. These authors found elevated
BNP in stroke patients who had sinus rhythm on admission, but
developed AF during follow-up. Within our cohort, the prevalence
of paroxysmal AF is nearly three times higher in patients with NT-
proBNP above the median of 239 pg/ml compared to those with
NT-proBNP below median. However, the discriminatory value of
all natriuretic peptides for the detection of patients with
paroxysmal AF was only moderate (best area under the curve
0.747 for BNP) which limits the value of these biomarkers in
patients with cerebral ischemia. We found similar results for
biomarkers in the detection of paroxysmal AF in patients with
hypertension, but without prior stroke (unpublished data). BNP
was the only natriuretic peptide to be predictive for paroxysmal
AF in multivariate analyses. This discrepancy between previous
reports of natriuretic peptides as predictors of future atrial
fibrillation and elevated levels in persistent atrial fibrillation may
well be explained by the population studied and our study design:
To reflect a real-life stroke scenario, we included an unselected
cohort of patients with cerebral ischemia, rather heterogeneous
and with many comorbidities. This may increase variability in
biomarker plasma levels due to cofactors. A second factor that may
Figure 1. Study flow of the Find-AF trial. 281 patients were
included, 237 had sinus rhythm on the admission ECG. 1 patient
withdrew consent, 16 patients were excluded from the analysis for
different reasons, given a total of 220 study participants analysed.
doi:10.1371/journal.pone.0034351.g001
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AF may have been its very early measurement in the emergency
department. As a stroke may be associated with acute hemody-
namic perturbations, natriuretic peptide levels might be altered by
the index event itself. However, only an unselected cohort like the
one included in Find-AF can be truly informative about the value
of a diagnostic method in clinical practice. Another important
factor may be the use of 7 d Holter monitoring for the diagnosis of
paroxysmal AF. Because this method is more sensitive to detect
paroxysmal AF in these patients, we probably identified patients
with a lower burden of AF than in most other studies. Especially
asymptomatic patients and those with only short episodes of AF
may experience less hemodynamic compromise and therefore
have lower natriuretic peptide levels than those with longer
episodes or severe symptoms that allow a clinical diagnosis in
studies with less sensitive diagnostic methods.
Table 1. Patient characteristics.




Age 67613 76612 0.001
Female gender 80 (41.7%) 12 (42.9%) 0.905
BMI 27.565.7 26.864.7 0.484
NIH-SS 3647 64 ,0.001
Modified Rankin Scale 2613 61 ,0.001
Stroke severity
{ TIA 68 (35.4%) 2 (7.1%) 0.001
Minor stroke 52 (27.1%) 6 (21.4%)
Major stroke 72 (37.5%) 20 (71.4%)
TOAST classification Large artery atherosclerosis 39 (20.3%) 0 (0.0%) 0.008
Cardioembolic 28 (14.6%) 11 (39.3%)
Lacunar/small vessels 27 (14.1%) 0 (0.0%)
Rare/other causes 5 (2.6%) 0 (0.0%)
Undetermined cause 93 (48.4%) 17 (60.7%)
Heart rate 72613 71616 0.656
Systolic blood pressure 143622 154626 0.010
Diastolic blood pressure 79613 80614 0.489
Creatinine [mg/dl] 1.060.5 1.060.5 0.616
Estimated glomerular filtration rate (ml/min/1,73 m
2)8 4 626 76626 0.133
Hemoglobin [mg/dl] 13.961.7 13.261.8 0.033
TSH [iU/ml] 2.6611.3 2.263.2 0.864
Left atrial diameter [mm] 41674 4 66 0.050
Left ventricular ejection fraction [%] 62695 9 610 0.309
Left ventricular mass index [g/m
2]2 1 9 679 222659 0.857
History of stroke 29 (15.1%) 5 (17.9%) 0.707
History of TIA 18 (9.4%) 2 (7.1%) 0.701
Heart failure 10 (5.2%) 2 (7.1%) 0.674
Hypertension 136 (70.8%) 23 (82.1%) 0.212
Diabetes 43 (22.4%) 7 (25.0%) 0.759
Smoker 51 (26.6%) 4 (14.3%) 0.062
Hyperlipidemia 60 (31.3%) 14 (50.0%) 0.056
Coronary artery disease 22 (11.5%) 11 (39.3%) 0.001
Peripheral artery disease 5 (2.6%) 2 (7.1%) 0.201
Medication
ACE inhibitors/ARBs 106 (55.2%) 15 (53.6%) 0.968
Beta-blockers 71 (37.0%) 16 (57.1%) 0.067
Calcium antagonists 34 (17.7%) 2 (7.1%) 0.255
Statins 46 (24.0%) 12 (42.9%) 0.059
Antiarrhythmics 2 (1.0%) 0 (0.0%) 0.601
{Minor stroke resolved completely within 30 days or change in NIH stroke scale by 3 points; major stroke neurologic deficit persisted after 30 days and increased NIH
stroke scale by 3 points.
ARB: Angiotensin receptor blocker.
doi:10.1371/journal.pone.0034351.t001
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natriuretic peptide levels was not different between patients with
and without AF, although it has convincingly been demonstrated
that the main cardiac source of natriuretic peptide release in AF
are the atria [17] and that the plasma levels fall after conversion
from AF to sinus rhythm [12]. Two mechanisms may explain this
finding:
1. NT-proBNP increased from baseline to 6 and 24 hours after
the index event in all patients irrespective of paroxysmal AF.
This may be explained by a release of NT-proBNP reflecting a
vasodilating response to the cerebral ischemic event or a direct
myocardial dysfunction [18]. Patients with paroxysmal AF had
larger strokes (median NIH stroke scale 7 vs. 3) and had a
higher morbidity (mRS 3 vs. 2). Thus, a decrease in NT-
proBNP released from the heart may have been counterbal-
anced by an increase in NT-proBNP released from brain tissue
resulting in a lack of difference in NT-proBNP between the two
groups. However, the absence of a difference in NT-proANP
levels argues against this hypothesis.
2. The time difference between conversion to sinus rhythm and
the cerebral ischemic events was longer than assumed. Earlier
studies have shown that it takes up to 4 weeks after electric
cardioversion for a restoration of atrial contraction [19] and
that the risk for thromboembolism is increased in patients
without anticoagulation especially within the first days after
Figure 2. NT-proBNP and NT-proBNP ratio and paroxysmal atrial fibrillation. Left panel: Percentage of study participants with paroxysmal
atrial fibrillation on Holter monitoring in the two sub-groups of patients with NT-proBNP plasma levels below and above the median NT-proBNP
plasma level (239 pg/ml). Right panel: Percentage of study participants with paroxysmal atrial fibrillation below and above the median ratio of early
(0 h) to late (24 h) NT-proBNP plasma level (0.78).
doi:10.1371/journal.pone.0034351.g002
Table 2. Natriuretic peptides plasma levels at three different timepoints and the ratio of early (0 h) to late (24 h) natriuretic
peptide level.
n=




NT-proBNP 0 h (pg/ml) 201 195 (74–564) 467 (212–872) 0.023
NT-proBNP 6 h (pg/ml) 192 260 (90–883) 635 (256–1334) 0.029
NT-proBNP 24 h (pg/ml) 207 276 (94–902) 983 (297–1785) 0.004
Ratio (NT-proBNP 0 h/NT-proBNP 24 h) 188 0.79 (0.48–1.09) 0.68 (0.38–0.88) 0.078
BNP 0 h (pg/ml) 178 104 (50–189) 181 (133–384) ,0.001
BNP 6 h (pg/ml) 181 108 (53–251) 321 (170–564) ,0.001
BNP 24 h (pg/ml) 194 116 (46–253) 336 (188–838) ,0.001
Ratio (BNP 0 h/BNP 24 h) 156 0.93 (0.63–1.26) 0.64 (0.43–0.96) 0.027
NT-proANP 0 h (pg/ml) 197 84000 (46291–128778) 114206 (95142–163170) 0.007
NT-proANP 6 h (pg/ml) 190 79774 (40607–116863) 102715 (82224–132688) 0.029
NT-proANP 24 h (pg/ml) 202 68199 (43400–118676) 118379 (77422–140828) 0.007
Ratio (NT-proANP 0 h/NT-proANP 24 h) 180 1.20 (0.90–1.50) 1.24 (0.90–1.62) 0.708
All data are displayed as median (25%–75% percentile). Data are compared by Mann-Whitney-U-Test.
doi:10.1371/journal.pone.0034351.t002
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place several days before the index event (cerebral ischemia),
there might be no relevant decrease in NT-proBNP plasma
levels in the first 24 hours after the index event.
Strengths and limitations
Our study is strengthened by its size and the prospective
evaluation of natriuretic peptide levels as a primary objective.
Moreover, the use and detailed analysis of 7 day-Holter ECG for
the evaluation of paroxysmal AF allowed detecting a high number
of affected patients, superior to periodic ECGs and cardiac event
loop recorders [20]. However, we can not exclude that a larger
number of patients with paroxysmal AF may have been detected
(e. g. longer duration of Holter ECG monitoring or implantable
loop recorders).
Clinical implications
The most relevant complication of untreated AF is cerebral
ischemia and systemic embolism and it has convincingly been
shown that this risk is similar in paroxysmal and sustained
(persistent or permanent) AF [21]. Patients with cerebral ischemia
and AF have an indication for oral anticoagulation, independent
of AF type, and oral anticoagulation is capable to cut down the risk
for recurrent stroke by nearly 2/3 [22]. Thus, the identification of
an increased risk for paroxysmal AF by a natriuretic peptide is
highly attractive and clinically relevant in patients presenting with
acute cerebral ischemia and sinus rhythm. We have previously
shown that 7 d Holter monitoring increases the diagnostic yield for
paroxysmal AF in these patients. Our data show that BNP is the
only independent predictor of paroxysmal AF. If only patients with
a BNP.99 pg/ml would have been screened by 7 day Holter
ECG, this would have reduced the number of patients needing 7
day Holter ECG by 42% with only 8% of patients with
paroxysmal AF being missed.
Summary
Although natriuretic peptide levels are higher in stroke patients
with paroxysmal AF compared to patients with permanent sinus
rhythm, our prospective investigation shows that BNP is the only
natriuretic peptide independently predictive of paroxysmal atrial
fibrillation. BNP may therefore be used as a rapidly available tool
for early risk stratification in patients with cerebral ischemia.
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